Managing dyskinesia requires understanding the specific needs of each person affected by this condition, which causes involuntary movements. Treatment approaches focus on adjusting medications, exploring newer therapies, and supporting quality of life through careful monitoring and individualized care plans.

Understanding How Treatment Works for Dyskinesia

The goal when treating dyskinesia is not simply to eliminate movements, but to help people live comfortably with the condition or reduce movements that interfere with daily activities. Because dyskinesia most commonly develops as a complication of medications used to treat other conditions—especially Parkinson’s disease—doctors must carefully balance managing the underlying condition while minimizing unwanted movements. This balancing act is at the heart of dyskinesia treatment.

Treatment decisions depend heavily on how bothersome the movements are, what is causing them, and whether the person needs to continue taking the medication that triggered the dyskinesia. Some people experience mild movements that barely affect their lives, while others have severe dyskinesia that interferes with work, social activities, or even basic tasks like eating and dressing. The approach taken will differ significantly between these two scenarios.

It is important to understand that not all dyskinesia requires aggressive treatment. Many people with Parkinson’s disease, for instance, find that having some dyskinesia is preferable to experiencing severe stiffness and immobility when their medication wears off. This preference guides treatment planning and emphasizes the importance of patient input in deciding on the best course of action.^[1]

Standard Approaches to Treating Dyskinesia

The first line of treatment for dyskinesia typically involves adjusting the medication that is causing the problem. For people taking levodopa—the most common Parkinson’s medication—this might mean changing the dose or timing of when the medication is taken. The aim is to provide enough medication to control the underlying symptoms, such as tremor and stiffness, without pushing dopamine levels so high that dyskinesia develops.^[1]

Doctors may switch patients to extended-release formulations of levodopa or other dopamine-related medications. These longer-acting versions help maintain steadier levels of dopamine in the brain, which can reduce the peaks and valleys that contribute to dyskinesia. One example is Rytary, an extended-release form of levodopa. Another option is Duopa, a gel form of levodopa that is delivered continuously through a pump directly into the small intestine, providing a more consistent supply throughout the day.^[11]

When medication adjustments alone are not sufficient, doctors may add amantadine to the treatment plan. Amantadine works on the glutamate system in the brain—a different chemical pathway from dopamine—to help reduce dyskinesia. The extended-release version, known as Gocovri, was specifically approved by the FDA in 2017 for treating dyskinesia in people with Parkinson’s disease. Before Gocovri became available, immediate-release amantadine was often used for this purpose, and it is still prescribed in some situations.^[11]

For people with tardive dyskinesia—a type of dyskinesia caused by long-term use of drugs that block dopamine receptors, such as antipsychotics—the approach may differ. If possible, doctors will try to reduce the dose of the offending medication or switch to a different drug with a lower risk of causing tardive dyskinesia. Atypical antipsychotics, such as risperidone and clozapine, generally have a lower risk compared to older, traditional antipsychotic medications.^[10]

Unfortunately, stopping or reducing the medication does not guarantee that tardive dyskinesia will resolve. The movements can persist even after the drug is discontinued, which makes prevention and early detection critically important. For this reason, healthcare providers are encouraged to obtain informed written consent before starting any medication that carries a risk of tardive dyskinesia, ensuring patients are aware of this potential complication.^[10]

In addition to medication-based treatments, some people benefit from deep brain stimulation (DBS), a surgical procedure. DBS is not suitable for everyone, but it may be considered for individuals who have had Parkinson’s disease for several years, have significant dyskinesia that interferes with daily life, and have not responded adequately to medication adjustments. The procedure involves implanting electrodes in specific areas of the brain to help regulate abnormal movement signals.^[11]

Emerging and Experimental Treatments in Clinical Trials

Research into new treatments for dyskinesia is ongoing, with several promising therapies being tested in clinical trials. One class of drugs that has shown particular promise is VMAT2 inhibitors, which stands for vesicular monoamine transporter 2 inhibitors. These medications work by reducing the amount of dopamine released in the brain, which can help control the involuntary movements associated with tardive dyskinesia.^[12]

VMAT2 inhibitors represent a significant advancement because they target the underlying mechanism that drives dyskinesia rather than simply masking symptoms. These drugs are now part of the standard treatment arsenal for tardive dyskinesia and are being studied further to optimize their use and understand which patients benefit most from them.

Clinical trials are also exploring whether certain antioxidants might help prevent or reduce dyskinesia. The idea behind this research is that oxidative stress—a process where harmful molecules damage cells—may contribute to the development of dyskinesia. Some studies have investigated whether dehydroepiandrosterone (DHEA), an endogenous antioxidant produced by the body, might offer protective benefits. While this hypothesis is still being tested, the concept has generated interest because it suggests a possible neuroprotective strategy.^[10]

Another area of investigation involves surgical techniques. Small case reports and series have explored whether procedures like pallidotomy or thalamotomy—which involve creating lesions in specific brain regions—might help reduce dyskinesia. More recently, research has focused on deep brain stimulation targeting the internal globus pallidus, a brain structure involved in movement control. Early results have been encouraging, with several studies reporting notable improvements in motor symptoms without major psychiatric side effects.^[10]

Clinical trials for dyskinesia are conducted in phases to ensure safety and effectiveness. Phase I trials focus on determining whether a treatment is safe and identifying any side effects. Phase II trials evaluate whether the treatment is effective in reducing dyskinesia and in what doses. Phase III trials compare the new treatment to existing standard therapies to determine whether it offers additional benefits. Patients interested in participating in clinical trials should speak with their healthcare providers to learn about available studies and whether they might be eligible.

Trial locations vary widely, with studies being conducted in the United States, Europe, and other regions. Eligibility criteria typically include factors such as the type and severity of dyskinesia, the medications being taken, and the presence of other health conditions. Participation in clinical trials not only offers access to cutting-edge treatments but also contributes to the broader understanding of dyskinesia and how best to manage it.

Types of Dyskinesia and Their Treatment Implications

Understanding the different types of dyskinesia is important because treatment strategies may vary depending on when the movements occur and what triggers them. The most common type is peak dose dyskinesia, which happens when levodopa levels in the blood are at their highest—usually one to two hours after taking the medication. This timing typically coincides with when the medication is working best to control Parkinson’s symptoms. In the early stages, peak dose dyskinesia may be so mild that people do not even notice the extra movements.^[1]

Another form is diphasic dyskinesia, also called the dyskinesia-improvement-dyskinesia (D-I-D) syndrome. In this pattern, involuntary movements occur as the medication is just beginning to work (the “on” period) and again as it starts to wear off. This type of dyskinesia can be more challenging to manage because it does not follow the predictable peak pattern.^[1]

There is also tardive dystonia, a subtype of tardive dyskinesia where muscles that normally work together instead fight against each other, causing twisting or abnormal postures. Some people with tardive dystonia discover they can use “sensory tricks” to temporarily reduce or correct these muscle contractions. Examples include sucking on a straw to reduce tongue movements or rubbing an eyebrow to correct eyelid dystonia. Keeping detailed records of daily activities and symptoms can help identify these helpful tricks.^[12]

The specific type of dyskinesia influences treatment choices. For instance, peak dose dyskinesia may respond well to lowering the dose of levodopa or spreading it out over more frequent, smaller doses. Diphasic dyskinesia, on the other hand, may require switching to a continuous delivery system like the Duopa pump. Tardive dyskinesia may benefit more from VMAT2 inhibitors or switching to a different psychiatric medication.

Risk Factors and Who Is Most Affected

Not everyone who takes levodopa or dopamine-blocking medications will develop dyskinesia, but certain factors increase the risk. About half of people taking levodopa eventually develop dyskinesia, typically after five to ten years of treatment. Younger people with Parkinson’s disease are thought to be at higher risk of developing both motor fluctuations and dyskinesia earlier in their treatment journey.^[7][1]

High doses of levodopa taken over a long period increase the likelihood of dyskinesia. People who develop Parkinson’s before age 40 are at particularly high risk. Additionally, individuals with the akinetic-rigid type of Parkinson’s—characterized by stiff and slow movements without prominent tremors—may be more susceptible to dyskinesia than those whose primary symptom is tremor.^[7]

Stress is another contributing factor. Physical stress, such as illness or surgery, as well as psychological stress can worsen dyskinesia. Many people notice that their movements become more pronounced when they are anxious, excited, or in situations where they feel self-conscious. This connection between emotional state and symptom severity underscores the importance of stress management as part of comprehensive dyskinesia care.^[12]

For tardive dyskinesia, the main risk factor is long-term use of medications that block dopamine receptors. These include most antipsychotic drugs, but also some medications used to treat nausea, digestive problems, and other conditions. The longer someone takes these medications and the higher the dose, the greater the risk. However, tardive dyskinesia can develop even with short-term use, making vigilance important from the start of treatment.^[10]

Living Well with Dyskinesia

While treatment focuses on reducing or managing involuntary movements, living well with dyskinesia also involves building routines and support systems that promote overall well-being. Establishing a comfortable daily routine can help minimize stress, which in turn may reduce the frequency or severity of dyskinesia episodes. Regular exercise, particularly low-impact activities like yoga or swimming, has been shown to support both physical and mental health.^[13]

A balanced diet rich in fruits, vegetables, and whole grains supports general health and may help the body cope better with the demands of managing a chronic condition. Some people find that mindfulness practices, such as meditation or deep breathing exercises, help ease stress and improve emotional resilience.^[13]

Building a strong support network is equally important. Talking openly with family and friends about dyskinesia helps them understand what you are experiencing and how they can offer support. Many people benefit from joining support groups, either in person or online, where they can connect with others facing similar challenges. Organizations like the National Organization for Tardive Dyskinesia offer virtual support groups, educational materials, and information about clinical trials.^[12]

Keeping detailed records of symptoms, medications, and daily activities can be invaluable. This information helps healthcare providers identify patterns, adjust treatment plans, and sometimes uncover helpful sensory tricks that reduce symptoms. Apps and symptom trackers are available to make this process easier and more consistent.^[12]

Adapting to changes is another key aspect of living with dyskinesia. If movements affect the ability to perform specific tasks, exploring assistive tools and techniques can help maintain independence. Occupational therapy can teach strategies for navigating daily challenges, from eating and dressing to work-related tasks.

Staying positive and focusing on what can be controlled makes a significant difference. Celebrating small achievements, pursuing hobbies that bring joy, and remembering that each step forward is a victory all contribute to a fulfilling life. Advocacy is also important—staying informed about new treatments, asking questions during medical appointments, and speaking up about needs ensures that patients remain active participants in their care.^[13]

Most Common Treatment Methods

• Medication Adjustment
  • Changing the dose or timing of levodopa to control symptoms without causing excessive dyskinesia
  • Switching to extended-release formulations like Rytary to maintain steadier dopamine levels
  • Using continuous delivery systems such as Duopa gel infusion for consistent medication supply throughout the day
• Amantadine Therapy
  • Adding amantadine to target the glutamate system in the brain rather than dopamine pathways
  • Using Gocovri (extended-release amantadine), which was FDA-approved in 2017 specifically for dyskinesia
  • Prescribing immediate-release amantadine in some situations when extended-release is not suitable
• Antipsychotic Medication Changes
  • Reducing doses of dopamine-blocking drugs that cause tardive dyskinesia when medically safe
  • Switching to atypical antipsychotics like risperidone or clozapine, which have lower risk of causing tardive dyskinesia
  • Obtaining informed written consent before starting medications that carry dyskinesia risk
• VMAT2 Inhibitors
  • Using vesicular monoamine transporter 2 inhibitors to reduce dopamine release in the brain
  • Targeting the underlying mechanism of tardive dyskinesia rather than just masking symptoms
• Deep Brain Stimulation (DBS)
  • Implanting electrodes in specific brain areas to regulate abnormal movement signals
  • Considering surgery for people with Parkinson’s who have not responded adequately to medication adjustments
  • Targeting the internal globus pallidus to improve motor symptoms without major psychiatric side effects
• Supportive Care and Lifestyle Modifications
  • Engaging in regular low-impact exercise like yoga or swimming to support physical and mental health
  • Practicing mindfulness techniques such as meditation or deep breathing to manage stress
  • Working with occupational therapists to learn strategies for maintaining independence
  • Using sensory tricks to temporarily reduce involuntary movements in tardive dystonia